Peptide & GLP-1 News
Research updates, regulatory changes, and industry developments — reported with context, not hype.
PeptideMark tracks the peptide space with a single goal: help readers understand what the evidence actually shows. We cover FDA regulatory actions (503A rulings, new approvals, warning letters), clinical trial readouts (STEP, SURMOUNT, SELECT, and emerging programs), GLP-1 drug pipeline updates, compounding pharmacy developments, and the research that moves the field forward. Every article cites primary sources. For longer evergreen explainers and deep dives, see our Learn library.
Featured
Stanford Discovers "Natural Ozempic" Peptide That Cuts Appetite 50% Without GI Side Effects
Stanford researchers used an AI tool called Peptide Predictor to scan all 20,000 human protein-coding genes and discovered BRP — a naturally occurring 12-amino-acid peptide that reduced food intake by 50% in mice and minipigs without the GI side effects of semaglutide. The study was published in Nature.
Semaglutide Fails Alzheimer's Trial: What the EVOKE Results Mean for GLP-1 Brain Claims
The largest clinical trial of semaglutide for Alzheimer's disease — the EVOKE program, enrolling 3,808 patients across 566 sites in 40 countries — failed to slow cognitive decline. But the biomarker data tells a more nuanced story, and the Parkinson's evidence remains stronger.
FDA Sets July 23–24 Meeting to Review BPC-157, TB-500, and 5 More Peptides for Compounding Access
The FDA announced a formal advisory committee meeting on July 23–24 to evaluate whether seven peptides — including BPC-157, TB-500, and Semax — should be added to the 503A bulk drug substances list, restoring legal compounding access. A public comment docket is open until July 22.
RFK Jr. Announces 14 Peptides Moving Back to Category 1: What It Means
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides on the FDA Category 2 restricted list will return to Category 1 — restoring legal compounding access.
Ozempic Side Effects: What 5 Years of Real-World Data Actually Shows
With over 5 years of real-world prescribing data, the side effect profile of semaglutide is now well-characterized. We break down what the evidence shows — from common GI effects to the concerns making headlines.
Oral Wegovy Pill Gets FDA Approval: What You Need to Know
The FDA approved oral semaglutide (Wegovy pill) for chronic weight management in December 2025 — eliminating the need for weekly injections. Here is what the clinical data shows.
Tirzepatide vs. Semaglutide: What the Head-to-Head Trials Show
The SURMOUNT-5 trial settled the debate: tirzepatide produces 47% more weight loss than semaglutide. But the full picture is more nuanced than the headline.
Semaglutide vs Tirzepatide: Mechanisms, Efficacy, and Clinical Differences
Two of the most effective weight loss medications available are semaglutide and tirzepatide. Here we compare their mechanisms of action, clinical trial results, and practical differences for patients.
FDA Peptide Reclassification: March 2026 Status Update
One month after the announcement that 14 peptides would return to Category 1 compounding status, the formal FDA reclassification has not been published. Here is the latest on what is happening and what to expect.
What Happens When You Stop Taking Ozempic or Mounjaro? New 2026 Research
A major Cleveland Clinic study of nearly 8,000 patients found that stopping GLP-1 drugs does not lead to the dramatic weight regain many fear. Average regain was just 0.5% at one year. Here is what the research actually shows.
Survodutide: The Dual GLP-1/Glucagon Agonist Targeting Liver Disease and Obesity
Survodutide combines GLP-1 and glucagon receptor agonism to target both obesity and metabolic liver disease — a differentiated approach that could reshape MASH treatment.
Tirzepatide for Sleep Apnea: SURMOUNT-OSA Trial Shows Dramatic Results
The SURMOUNT-OSA trial demonstrated that tirzepatide reduced obstructive sleep apnea severity by up to 63%, with some patients achieving complete remission — potentially transforming treatment for 30+ million Americans.
Survodutide vs Tirzepatide vs Retatrutide: Next-Gen Weight Loss Drugs Compared
Three multi-agonist peptides are competing to define the next generation of obesity treatment. We compare their mechanisms, clinical data, and where each drug fits.
Are Peptides Legal in 2026? The Complete Post-RFK Status Guide
The legal landscape for peptides shifted dramatically in 2026 after HHS Secretary RFK Jr. moved 14 peptides back to Category 1. Here is exactly what is legal, what is not, and what it means for patients and researchers.
When Will Retatrutide Be FDA Approved? The 2026 Timeline Explained
With Phase 3 results showing 24% mean weight loss, retatrutide is poised to become the most effective weight-loss drug ever approved. But when will patients actually get it, and what does the timeline look like from here?
Foundayo (Orforglipron) FDA Approved: The First GLP-1 Pill You Can Take Any Time of Day
On April 1, 2026, the FDA approved Foundayo (orforglipron) — Eli Lilly's once-daily oral GLP-1 receptor agonist for weight loss. Unlike existing oral semaglutide, Foundayo can be taken any time of day without food or water restrictions, starting at $149/month.
FDA Removes 12 Peptides from Category 2: BPC-157, TB-500, Semax, and More No Longer Flagged as Safety Risks
On April 15, 2026, the FDA announced the removal of 12 peptide bulk drug substances from Category 2 — the list reserved for compounds with significant safety concerns. BPC-157, TB-500, Semax, MOTS-c, GHK-Cu (injectable), and seven others are affected. Here is what it means.
All Articles
New Study: Tirzepatide Causes More Muscle Loss Than Semaglutide in 8,000-Patient Analysis
A real-world analysis of 8,000 patients published in April 2026 found that tirzepatide caused significantly more lean body mass loss than semaglutide at every time point measured — raising new questions about the muscle cost of greater weight loss.
MK-677 (Ibutamoren) Legal Status and FDA Approval in 2026: The Complete Picture
MK-677 (ibutamoren) occupies one of the most confusing regulatory positions in the peptide world — not FDA-approved, not a controlled substance, WADA-banned, and now under FDA compounding review. Here is the full legal picture as of April 2026.
Retatrutide Phase 3: Triple Agonist Delivers 71 lbs Average Weight Loss
Eli Lilly's triple-agonist retatrutide delivered an average 71.2 lbs of weight loss in the TRIUMPH-4 Phase 3 trial — plus significant osteoarthritis pain relief. Seven more Phase 3 trials report in 2026.
Semaglutide Could Cost $3/Month: Patent Expiry and Generic Timeline
Analysis shows generic semaglutide could be produced for $3/month. With patents expiring in 8 countries in 2026, the cost landscape for Ozempic and Wegovy is about to change dramatically.
FDA Category 2 Peptide Ban: The Complete Guide
Everything you need to know about the FDA's Category 2 classification of peptides — which compounds are affected, what it means for access, and the 2026 reclassification reversal.
How to Prevent Muscle Loss on Ozempic and Other GLP-1 Drugs
Up to 40% of weight lost on GLP-1 drugs can be lean mass. The medical consensus is clear: resistance training during GLP-1 therapy is essential, not optional.
"Ozempic Face" Explained: What Causes It and What Helps
"Ozempic face" — facial sagging and volume loss during rapid weight loss — is not caused by semaglutide specifically. It happens with any significant weight loss. Here is what the evidence says.
Peptide Compounding in 2026: What Patients Need to Know
With the 2026 FDA reclassification restoring access to many peptides, compounding is back in focus. Here is what you need to know about quality, safety, and choosing a pharmacy.
GLP-1 Drugs and Cancer Risk: What the Research Actually Shows
The thyroid cancer boxed warning. The cancer-protective speculation. A 50-trial meta-analysis. Here is what the evidence actually says about GLP-1 medications and cancer risk.
2026 Weight Loss Drug Pipeline: What Comes After Ozempic
Retatrutide, orforglipron, CagriSema, and more — the next wave of obesity drugs promises even greater weight loss, oral delivery, and new mechanisms. Here is the full pipeline.
Tirzepatide 3-Year Data: Weight Loss Sustained at 22.9%
The SURMOUNT-1 three-year extension confirms what patients needed to know: tirzepatide weight loss holds steady through year 3 with continued treatment.
Eli Lilly Warns of Counterfeit Tirzepatide: How to Stay Safe
Eli Lilly is pursuing legal action against sellers of counterfeit tirzepatide. Testing found products containing bacteria, impurities, and in one case only sugar alcohol.
How GLP-1 Drugs Are Cutting America's Grocery Bills
A Cornell study found households on GLP-1 drugs cut grocery spending by over 5% within 6 months, with even bigger drops at fast-food restaurants. The food industry is taking notice.
BPC-157 Human Clinical Data: Where We Stand in 2026
With the FDA reclassification restoring compounding access, BPC-157 is back in focus. Here is an honest assessment of where the human evidence stands.
Novo Nordisk Slashes GLP-1 Prices 70%: What It Means for Patients
Novo Nordisk announced up to 70% price cuts on its GLP-1 medications in early 2026. We analyze what this actually means for patient out-of-pocket costs.
FDA Approves Monthly Tirzepatide KwikPen for Weight Management
The new Zepbound KwikPen packs 4 weekly doses into one device — a full month of treatment. Available at $299/month for the starting dose via LillyDirect.
GLP-1 Drugs and Reduced Alcohol Consumption: An Unexpected Effect
Patients on Ozempic and Wegovy increasingly report reduced desire to drink alcohol. The neuroscience behind this effect is becoming clearer — and clinical trials are underway.
Peptides Go Mainstream: NPR, MIT Tech Review, and PolitiFact Cover the Trend
In a single week in February 2026, NPR, MIT Technology Review, and PolitiFact all published major pieces on the peptide trend. We analyze their coverage.
BPC-157 vs TB-500: Recovery Peptides Compared
BPC-157 and TB-500 are two peptides heavily promoted for tissue repair and recovery. We review what animal research actually shows and how they differ mechanistically.
Ipamorelin vs CJC-1295: GH Secretagogues Compared
Ipamorelin and CJC-1295 are two distinct GH secretagogues often used together. We explain how they work, why they are stacked, and what evidence exists.
MK-677 vs Sermorelin: Oral Non-Peptide vs Injectable GHRH
MK-677 and sermorelin both boost growth hormone but work differently and have different routes of administration. We compare mechanisms, evidence, and practical trade-offs.
Selank vs Semax: Russian Nootropic Peptides Compared
Selank and semax are two Russian-developed nootropic peptides claimed to enhance cognition and mood. We explain how they differ and what evidence exists.
Ozempic vs Mounjaro: GLP-1 vs GLP-1/GIP Dual Agonist Comparison
Ozempic (semaglutide) and Mounjaro (tirzepatide) are the two most popular GLP-1 receptor agonists for weight loss. Mounjaro adds GIP receptor agonism for potentially superior efficacy, but costs more. Here's a detailed breakdown.
MK-677 vs Ipamorelin: Oral Secretagogue vs Injectable Peptide
MK-677 (oral growth hormone secretagogue) and Ipamorelin (injectable peptide GH releaser) both stimulate growth hormone, but differ fundamentally in mechanism, potency, and side effects. Here's the detailed comparison.
MK-677 vs CJC-1295: Ghrelin Mimetic vs GHRH Analog
MK-677 and CJC-1295 both stimulate growth hormone but target different pathways. MK-677 mimics ghrelin; CJC-1295 is a GHRH analog. Here's how they compare.
Sermorelin vs Ipamorelin: GHRH vs GHRP Growth Hormone Release
Sermorelin is FDA-approved for growth hormone deficiency; Ipamorelin is investigational. Both stimulate GH but through different mechanisms. Here's the comprehensive comparison.
BPC-157 vs GHK-Cu: Healing Peptide Comparison for Tissue Repair
Both BPC-157 and GHK-Cu are popular healing peptides. BPC-157 targets broad tissue repair; GHK-Cu has topical availability and collagen-promoting effects. Here's the detailed comparison.
Semaglutide vs Retatrutide: Single vs Triple Agonist Weight Loss
Retatrutide is a next-generation triple agonist (GLP-1/GIP/GCG) showing even greater weight loss than tirzepatide. Semaglutide is approved and widely available. Here's how they compare.
PT-141 vs Melanotan II: Melanocortin Agonists and Sexual Function
PT-141 is FDA-approved for sexual dysfunction; Melanotan II is experimental and carries significant safety concerns. Here's the comprehensive comparison of these melanocortin agonists.
Sermorelin vs CJC-1295: Short-Acting vs Long-Acting GHRH Analogs
Both sermorelin and CJC-1295 are GHRH analogs that stimulate growth hormone. The key difference is half-life: sermorelin requires frequent dosing; CJC-1295 (especially with DAC) requires fewer injections. Here's the detailed comparison.
Tesamorelin vs Sermorelin: GHRH Analogs Compared
Both are GHRH analogs that stimulate growth hormone release, but tesamorelin's trans-3-hexenoic acid modification gives it superior half-life and receptor binding.
AOD-9604 vs Semaglutide: Fat Loss Peptides Compared
AOD-9604 and semaglutide are often compared for fat loss, but their evidence profiles differ dramatically: semaglutide has extensive Phase 3 data and FDA approval; AOD-9604 failed Phase 2b trials.
Tirzepatide vs Retatrutide: Dual vs Triple GIP/GLP-1/Glucagon Agonists
Tirzepatide is FDA-approved for weight loss with robust efficacy (20-22% weight loss). Retatrutide adds glucagon receptor agonism for potentially superior outcomes, but remains in Phase 3 trials.
BPC-157 vs Sermorelin: Tissue Repair vs GH Stimulation
BPC-157 and sermorelin are frequently discussed together but target entirely different pathways: BPC-157 promotes tissue repair; sermorelin stimulates growth hormone. Understanding these differences is essential.
Ipamorelin vs MK-677: GHRP vs Ghrelin Agonist
Ipamorelin (GHRP) and MK-677 (ghrelin agonist) both stimulate GH but through different receptors and mechanisms. This is the reverse of our MK-677 vs Ipamorelin article with distinct framing.
TB-500 vs GHK-Cu: Thymosin vs Copper Peptide Healing
TB-500 and GHK-Cu are both healing peptides but target different pathways: TB-500 regulates actin; GHK-Cu activates copper-dependent gene expression and collagen synthesis.
CJC-1295/Ipamorelin Stack vs Sermorelin: Combo vs Single Agent
The CJC-1295/ipamorelin stack combines GHRH + GHRP for theoretical synergy. Sermorelin is a single GHRH agonist. Do combinations outperform single agents?
Thymosin Alpha-1 vs BPC-157: Immune Modulation vs Tissue Repair
Thymosin alpha-1 modulates immunity and is approved in 35+ countries. BPC-157 promotes tissue repair but lacks human efficacy trials. Very different peptides for different purposes.
Epithalon vs GHK-Cu: Telomerase Activation vs Copper-Dependent Repair
Epithalon targets telomerase and cellular aging; GHK-Cu activates copper-dependent enzymes for collagen synthesis. Both claim anti-aging benefits, but evidence profiles differ significantly.
Melanotan II vs PT-141: Melanocortin Peptides Compared
Side-by-side comparison of Melanotan II and PT-141, two melanocortin receptor agonists used for tanning and sexual function enhancement.
MK-677 vs Sermorelin: Oral vs Injectable GH Booster
Side-by-side comparison of MK-677 and sermorelin, two growth hormone secretagogues with different administration routes and profiles.
NAD+ vs Epithalon: Anti-Aging Approaches Compared
Two distinct anti-aging approaches: NAD+ (cellular energy) and epithalon (telomere-focused). Evidence, mechanisms, and practical comparison.
MOTS-c vs AOD-9604: Metabolic Peptides Compared
MOTS-c and AOD-9604 are both metabolic peptides, but target different pathways: mitochondrial function vs. lipolysis and metabolic rate.
Semaglutide vs AOD-9604: Weight Loss Evidence Gap
Semaglutide has robust evidence for weight loss; AOD-9604 has minimal evidence. Direct comparison of proven vs. experimental weight loss peptides.
BPC-157 vs Thymosin Alpha-1: Repair vs Immunity
BPC-157 focuses on tissue repair and healing; thymosin alpha-1 targets immune restoration. Two distinct therapeutic peptides with different applications.
Retatrutide vs AOD-9604: Next-Gen vs Legacy Weight Loss
Retatrutide is a newer triple GLP-1/GIP/GCG agonist showing superior weight loss vs. legacy compounds like AOD-9604.
Selank vs NAD+: Cognitive Enhancement Approaches
Selank and NAD+ both support cognition but via different pathways: anxiolytic vs. mitochondrial enhancement.
Best Peptides for Joint Pain: Evidence-Based Guide 2026
Comprehensive guide to peptides with evidence for joint pain management, including tissue repair and metabolic support compounds.
Best Peptides for Gut Health: Research & Evidence 2026
Comprehensive guide to peptides with evidence for improving gut barrier function, reducing inflammation, and supporting GI health.
Best Peptides for Sleep: What the Research Shows
Comprehensive guide to peptides supporting sleep quality, including GH secretagogues that leverage natural sleep physiology.
Best Peptides for Hair Loss: Evidence Review 2026
Comprehensive guide to peptides with evidence for hair growth support, including collagen stimulation and immune approaches.
Best Peptides for Skin: Anti-Aging & Rejuvenation Research
Comprehensive guide to peptides supporting skin rejuvenation, collagen synthesis, and anti-aging via multiple mechanisms.
Best Peptides for Immune Support: Evidence Guide 2026
Comprehensive guide to peptides supporting immune function, T-cell restoration, and immune tolerance in aging and disease.
Best Peptides for Fat Loss: Complete Evidence Ranking 2026
Comprehensive guide ranking peptides for weight loss by evidence strength. GLP-1s dominate; experimental compounds lag far behind.
Best Peptides for Injury Recovery: Research Guide 2026
Comprehensive guide to tissue-healing peptides supporting recovery from muscle, joint, tendon, and ligament injuries.
Best Peptides for Bodybuilding: Evidence Review 2026
Research-backed guide to peptides that support muscle growth and recovery in bodybuilding. Evidence review of GH secretagogues versus traditional performance methods.
Best Peptides for Women: Safety & Evidence Guide 2026
Research guide to peptides specifically safe and effective for women. Coverage of FDA-approved options, gender-specific data, and honest evidence review.
Best Peptides for Men Over 40: Evidence-Based Options
Evidence-based guide to peptides for men over 40. Addresses natural GH decline, metabolic changes, and recovery with honest assessment of research.
Best Nootropic Peptides: Cognitive Function Research 2026
Evidence-based guide to peptides that support cognitive function, memory, and neuroprotection. Honest assessment of current research quality.
Best Peptides for Longevity: Anti-Aging Research 2026
Research into peptides for lifespan extension and healthspan. Honest assessment of telomerase, NAD+, mitochondrial, and collagen-focused approaches with realistic limitations.
Best Peptides for Inflammation: Research Guide 2026
Research guide to peptides that reduce inflammation. Coverage of BPC-157 anti-inflammatory mechanisms, immune modulation, and realistic anti-inflammatory benefits.
Best Peptides for Tendon Repair: Evidence Review 2026
Research guide to peptides for tendon and connective tissue repair. Focus on musculoskeletal healing with honest assessment of limited human data.
Peptide Therapy Cost Breakdown 2026: What You Will Actually Pay
Peptide therapy pricing varies enormously based on compound, source, and delivery model. This is a transparent breakdown of what patients actually pay in 2026, from $20/month sermorelin to $1,300/month retatrutide-class drugs.
Semaglutide Microdosing: The 2026 Trend, Benefits & Risks Explained
Semaglutide microdosing — using 0.1-0.25 mg weekly instead of the standard 2.4 mg — has exploded in popularity in 2026. Does the research support it, or is it a trend built on anecdote?
Why GLP-1 Drugs Don't Work for 10% of People: Stanford Identifies the PAM Gene Variant Behind GLP-1 Resistance
A Stanford Medicine study published in Genome Medicine found that roughly 10% of people carry genetic variants in the PAM enzyme that reduce their response to GLP-1 drugs like semaglutide and tirzepatide — a finding that could reshape how doctors prescribe weight loss and diabetes medications.
MariTide: Amgen's Monthly Weight Loss Injection That Could Replace Weekly GLP-1 Shots
Amgen's MariTide (maridebart cafraglutide) is an antibody-peptide conjugate that could deliver ~20% weight loss with just one injection per month — potentially disrupting the weekly GLP-1 injection market dominated by Ozempic and Zepbound.
CagriSema Phase 3 Results: 20% Weight Loss in REDEFINE Trials, Novo Nordisk Files for FDA Approval
Novo Nordisk's CagriSema — the combination of semaglutide and cagrilintide (an amylin analog) — achieved 20.4% weight loss in the Phase 3 REDEFINE 1 trial, with 60% of participants losing at least 20% of body weight. The company filed for FDA approval in December 2025.